Results 211 to 220 of about 9,649,206 (293)

Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors. [PDF]

open access: yesSci Rep, 2020
Karda R   +17 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

open access: yesBiotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga   +2 more
wiley   +1 more source

Cryo‐EM Analysis of Adenovirus Vector Reveals Purification Conditions Leading to Loss of Viral Fiber Proteins and Reduced Infectivity

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Vaccines and gene therapies require efficient delivery of genetic material to host cells. Viral vectors leverage viruses' ability to enter host cells to achieve this. Following the SARS‐CoV‐2 vaccine and novel gene therapies that utilize adenovirus vectors, there has been an increase in the demand for large‐scale production of vectors.
Betsy Widdicombe   +7 more
wiley   +1 more source

Efficient Cell Removal and Impurity Reduction for Poxvirus Purification in a Single Step Alluvial Filtration

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Modified Vaccinia virus Ankara (MVA) is a potent vector for the development of vaccines and novel cancer treatment strategies. Since it is a non‐replicating virus in human recipients, high infective titers are required for therapeutic efficacy.
Linus G. Weber   +5 more
wiley   +1 more source

Serotype‐Tailored Midstream and Downstream Operations to Advance the Manufacturing of Adeno‐Associated Viral Vectors

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Adeno‐associated viruses (AAVs) are the leading vectors for in vivo gene therapy, fueling a growing demand for scalable and robust biomanufacturing processes. Yet, the impact of cell lysis conditions on the performance of midstream and downstream unit operations across serotypes remains poorly characterized.
Arianna Minzoni   +20 more
wiley   +1 more source

Continuous Capture of Recombinant Adeno‐Associated Virus Particles Using Twin‐Column CaptureSMB

open access: yesBiotechnology and Bioengineering, EarlyView.
Continuous twin‐column CaptureSMB enables direct capture of secreted rAAV5 from minimally processed perfusion harvest, bypassing lysis, clarification, and concentration steps. Compared to batch capture, it achieves higher yield (+14.3%), greater productivity (+11.4%), and drastically reduced buffer use (−79.2%), while maintaining critical quality ...
Julia M. Müller   +11 more
wiley   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

open access: yesBiotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing   +2 more
wiley   +1 more source

High‐throughput development and scale‐up of recombinant adeno‐associated virus 5 anion‐exchange chromatography for high‐purity capsid separation

open access: yesBiotechnology Progress, EarlyView.
High‐throughput anion‐exchange chromatography process development enables scalable purification of high‐purity recombinant adeno‐associated virus capsids. Abstract Recombinant adeno‐associated virus (rAAV) production commonly yields a high proportion of empty and partially filled capsids, necessitating downstream purification to enrich full capsids ...
Kevin Vera   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy